Delta-Fly Pharma Inc
TSE:4598
Intrinsic Value
Delta-Fly Pharma, Inc. engages in the manufacturing, sale, research and development of pharmaceutical products for cancer treatment. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of Delta-Fly Pharma Inc.
Delta-Fly Pharma Inc's market capitalization is 6.5B JPY.
Delta-Fly Pharma Inc stock price is 794 JPY.
Delta-Fly Pharma Inc.
Delta-Fly Pharma Inc. Open DCF Valuation
Delta-Fly Pharma Inc. Open Relative Valuation
Delta-Fly Pharma Inc.
Delta-Fly Pharma Inc's ROE (Return on Equity) has significantly decreased in the last 3 years from -42% to -104%, and is approaching profitability.
Delta-Fly Pharma Inc's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -588% to -2 106%, and is approaching profitability.
Delta-Fly Pharma Inc has negative Operating Income for the last twelve months.
Delta-Fly Pharma Inc has negative Net Income for the last twelve months.
Delta-Fly Pharma Inc's ROE (Return on Equity) for the past 12 months is negative and is equal to -104%.
Delta-Fly Pharma Inc's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -2 106%.
Delta-Fly Pharma Inc has negative Free Cash Flow for the last twelve months.
Delta-Fly Pharma Inc has negative three-year average ROE (Return on Equity): -97%. The company is not efficient at transforming stockholders' equity into net income.
Delta-Fly Pharma Inc has negative three-year average ROIC (Return on Invested Capital): -1 515%. The company is not efficient at using invested capital to generate operating income.
Delta-Fly Pharma Inc's short-term assets (2B JPY) exceed its short-term liabilties (91m JPY).
Delta-Fly Pharma Inc's long-term assets (2B JPY) exceed its long-term liabilties (91m JPY).
Delta-Fly Pharma Inc's D/E (Debt to Equity) is very low and is equal to 0.
Delta-Fly Pharma Inc's Altman Z-Score is very high and is equal to 46.63.
Fundamental Analysis
Delta-Fly Pharma Inc
Balance Sheet Decomposition
Delta-Fly Pharma Inc
| Current Assets | 1.7B |
| Cash & Short-Term Investments | 1.7B |
| Other Current Assets | 12.2m |
| Non-Current Assets | 40.1m |
| PP&E | 38.2m |
| Other Non-Current Assets | 2m |
| Current Liabilities | 91m |
| Other Current Liabilities | 91m |
Earnings Waterfall
Delta-Fly Pharma Inc
|
Revenue
|
0
JPY
|
|
Operating Expenses
|
-1.2B
JPY
|
|
Operating Income
|
-1.2B
JPY
|
|
Other Expenses
|
-24.6m
JPY
|
|
Net Income
|
-1.3B
JPY
|
Free Cash Flow Analysis
Delta-Fly Pharma Inc
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Delta-Fly Pharma Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Delta-Fly Pharma Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Delta-Fly Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Delta-Fly Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Delta-Fly Pharma Inc
Shareholder Return
Price
Delta-Fly Pharma Inc
| Average Annual Return | -14.33% |
| Standard Deviation of Annual Returns | 32.58% |
| Max Drawdown | -75% |
| Market Capitalization | 6.7B JPY |
| Shares Outstanding | 8 229 702 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Delta-Fly Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
Delta-Fly Pharma, Inc. engages in the manufacturing, sale, research and development of pharmaceutical products for cancer treatment. The company is headquartered in Tokushima-Shi, Tokushima-Ken and currently employs 11 full-time employees. The company went IPO on 2018-10-12. The firm's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.
You don't have any saved screeners yet
